Peronální vinorelbin den 1. a den 8. v kombinaci s karboplatinou v léčbě nemocných s pokročilým nemalobuněčným karcinomem plic (NSCLC): výsledky nerandomizované studie u neselektované populace 396 nemocných

Title in English	Oral vinorelbin Day 1 and 8 in combination with carboplatin in the treatment of patients withadvanced non-small cell lung cancer (NSCLC): Results of a non-randomized study of 396 non-selected patients
Authors	SKŘIČKOVÁ Jana KADLEC Bohdan VENCLÍČEK Ondřej JANÁSKOVÁ T. BARTOŠ J. CHALUPA J. KOLEK V. GRYGÁRKOVÁ I. ČOUPKOVÁ H. REITERER P.
Year of publication	2013
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	The evaluation of efficacy and safety of oral vinorelbin on day 1 and 8 in combination with carboplatin in the treatment of patients with advanced NSCLC was performed in 311 patients (78.5% men, 21.5% women, median age 65 years). A median of 4 cycles was administered. Vinorelbin was well tolerated, requiring a dose reduction in only 7.1% patients while escalation was possible in 19.5% patients. The dose of oral vinorelbin could remain unchanged in 67.7% patients.